Sabino Strippoli
Overview
Explore the profile of Sabino Strippoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scarpato L, Palla M, Strippoli S, Tagliaferri L, Fania L, Saponara M, et al.
Dermatol Reports
. 2025 Mar;
17(1).
PMID: 40072471
Basal cell carcinoma (BCC) is the most common malignant tumor in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and...
2.
Azzariti A, De Summa S, Marvulli T, De Risi I, De Palma G, Di Fonte R, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):40.
PMID: 39910579
Background: Despite the high response rate to PD-1 blockade therapy in metastatic melanoma (MM) patients, a significant proportion of patients do not respond. Identifying biomarkers to predict patient response is...
3.
Tommasi S, Maurmo L, Rizzo A, Carella C, Ranieri G, De Summa S, et al.
Front Med (Lausanne)
. 2024 Nov;
11:1511339.
PMID: 39526241
[This corrects the article DOI: 10.3389/fmed.2024.1432628.].
4.
Tommasi S, Maurmo L, Rizzo A, Carella C, Ranieri G, De Summa S, et al.
Front Med (Lausanne)
. 2024 Sep;
11:1432628.
PMID: 39323465
Introduction: The management of cancer patients follows a Diagnostic Therapeutic and Care Pathway (PDTA) approach, aimed at achieving the optimal balance between care and quality of life. To support this...
5.
Comes M, Fucci L, Strippoli S, Bove S, Cazzato G, Colangiuli C, et al.
J Transl Med
. 2024 Sep;
22(1):838.
PMID: 39267101
Background: Risk stratification and treatment benefit prediction models are urgent to improve negative sentinel lymph node (SLN-) melanoma patient selection, thus avoiding costly and toxic treatments in patients at low...
6.
Squicciarini T, Villani R, Apollonio B, Fucci L, Zambetti M, Rossini M, et al.
Front Immunol
. 2024 May;
15:1369531.
PMID: 38799429
Background: Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by high immunogenicity which makes it particularly suitable for immune checkpoint inhibitors (ICIs) treatment. Case Presentation: We report the...
7.
Serrati S, Di Fonte R, Porcelli L, De Summa S, De Risi I, Fucci L, et al.
J Exp Clin Cancer Res
. 2023 Sep;
42(1):251.
PMID: 37759291
Background: Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1...
8.
Ascierto P, Di Giacomo A, Sileni V, Queirolo P, Spagnolo F, De Galitiis F, et al.
Eur J Cancer
. 2023 Aug;
191:113246.
PMID: 37549531
Introduction: The CheckMate 238 randomised study demonstrated the relevant benefit in terms of recurrence-free survival (RFS) of nivolumab versus ipilimumab in resected stage IIIB-C or IV melanoma patients with a...
9.
Di Fonte R, Strippoli S, Garofoli M, Cormio G, Serrati S, Loizzi V, et al.
Front Cell Dev Biol
. 2023 Jun;
11:1178316.
PMID: 37384250
Cervical cancer (CC) is characterized by genomic alterations in DNA repair genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs), such as trabectedin. Hence, we evaluated the...
10.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo A, et al.
Eur J Cancer
. 2023 Apr;
187:25-35.
PMID: 37099946
Background: Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1...